Category: Sanofi
-
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance
Lawyers representing generics makers welcomed the UPC’s decision to revoke the patent regardless of a prior EPO decision to the contrary.
-
UPC CoA reverses invalidation of Amgen patent, clarifies standards for added matter and sufficient disclosure; infringement action to resume
In a high-stakes life sciences case, the UPC’s CoA has provided its most far-reaching clarifications on (in)validity to date.